

# Jacquie Maignel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3598734/publications.pdf>

Version: 2024-02-01

9  
papers

175  
citations

1937685  
4  
h-index

1588992  
8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

184  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Expanding Therapeutic Utility of Botulinum Neurotoxins. <i>Toxins</i> , 2018, 10, 208.	3.4	79
2	Synthesis, Structure-Activity Relationships, and Pharmacological Profile of 9-Amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1- <i>h</i> indoles: Discovery of Potent, Selective Phosphodiesterase Type 4 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4850-4867.	6.4	46
3	Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models. <i>Science Advances</i> , 2019, 5, eaau7196.	10.3	29
4	Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems. <i>PLoS ONE</i> , 2017, 12, e0185628.	2.5	10
5	BoNT/A in the Urinary Bladder—More to the Story than Silencing of Cholinergic Nerves. <i>Toxins</i> , 2022, 14, 53.	3.4	5
6	New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency. <i>Toxins</i> , 2021, 13, 834.	3.4	3
7	The Isolated Mouse Jejunal Afferent Nerve Assay as a Tool to Assess the Effect of Botulinum Neurotoxins in Visceral Nociception. <i>Toxins</i> , 2022, 14, 205.	3.4	2
8	Exploring the effect of various BoNT serotypes in a model of autonomic nervous system hyperactivity from rodents and humans: Paving the way to better targeting therapeutics in autonomic disorders?. <i>Toxicon</i> , 2018, 156, S72.	1.6	1
9	BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study. <i>Toxins</i> , 2022, 14, 77.	3.4	0